Federation des caisses Desjardins du Quebec Grows Position in Johnson & Johnson $JNJ

Key Points

• The Federation des caisses Desjardins du Quebec increased its stake in Johnson & Johnson by 3.4%, owning 727,077 shares valued at $120.58 million.
• Analysts have mixed ratings on JNJ shares, with a consensus rating of "Moderate Buy" and an average target price of $176.29.
• Johnson & Johnson reported a strong quarterly performance with $2.77 EPS and revenue of $23.74 billion, exceeding analyst expectations.

Federation des caisses Desjardins du Quebec boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 727,077 shares of the company's stock after acquiring an additional 23,892 shares during the quarter. Federation des caisses Desjardins du Quebec's holdings in Johnson & Johnson were worth $120,580,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of JNJ. Highline Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $52,000. 69.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Price Performance

Shares of JNJ stock traded down $0.35 during trading on Wednesday, hitting $177.71. The company had a trading volume of 6,832,001 shares, compared to its average volume of 7,666,583. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock's 50-day moving average is $167.53 and its two-hundred day moving average is $160.45. The stock has a market capitalization of $427.98 billion, a price-to-earnings ratio of 19.01, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.